Skip to main content
Premium Trial:

Request an Annual Quote

GeneLink's Q1 Revenues Rise to $2M

NEW YORK (GenomeWeb News) – GeneLink today reported that its first-quarter revenues rose to $2 million from only $26,424 for the first quarter of 2008.

The Orlando, Fla.-based consumer genomics company said in a filing with the US Securities and Exchange Commission that the dramatic rise in its revenues was due to last year's launch of its GeneWize Life Sciences business and sales of its LifeMap Nutrition System product. GeneWize is directly selling to consumers nutritional products and skin care products that the firm said is specifically tailored to an individual's genetic makeup.

GeneLink posted a net loss of $510,229 for the quarter ended March 31, compared a net loss of $448,250 for Q1 2008. The higher loss was due to sales commission expenses of $733,025 paid to sales affiliates.

GeneLink finished the quarter with cash and cash equivalents of $676,251.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.